Patient Preferences for Lifestyle Management in a Multi-site Randomized Lifestyle Trial for Remission of the Metabolic Syndrome
International Journal of Behavioral Medicine · 2025-08 · 32 (4) · 486-494
DOI: 10.1007/s12529-024-10278-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Behavioral Medicine, online erschienen am 22.03.2024. Verfasst von Katherine Iannuzzelli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventative Medicine, Rush University Medical Center, Chicago, IL, USA. katherine.iannuzzelli@gmail.com. Hauptthemen laut MEDLINE: Metabolic Syndrome, Patient Preference, Life Style, Behavior Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: William G. McGowan Charitable Fund.
Abstract (Originalsprache)
Background
Randomized behavioral clinical trials are the gold standard for evaluating efficacy of a behavioral treatment. However, because participants are generally unblinded to treatment, preference for a specific treatment option can lead to biased results and/or reduced treatment efficacy. The purpose was to describe the relative frequency and correlates of existence of a preference and patient preference for either an in-person group-based or a remote self-directed, lifestyle treatment prior to randomization to one of these treatments.
Methods
The Enhanced Lifestyles for Metabolic Syndrome (ELM) trial is a multi-site behavioral clinical trial that compares efficacy of a group-based vs. a self-directed approach to lifestyle change on 2-year remission of the metabolic syndrome. Prior to randomization, participants were asked whether they had a preference for a particular treatment and, if so, which approach they preferred. Baseline data were used for a series of logistic regression models to determine behavioral correlates of treatment preference, independent of socioeconomic factors.
Results
Of the 331 participants, 131 (39.6%) had no preference for either treatment. Among the 200 with a preference, 56 (28.0%) preferred the self-directed program. Strength of a pre-existing habit of eating vegetables on most days was an independent correlate of no preference (adjusted OR, 1.27; 95% CI, 1.01–1.61; p = 0.03) and preference for a self-directed program (adjusted OR, 1.55; 95% CI, 1.09–2.22; p = 0.01).
Conclusion
A pre-existing habit of eating vegetables was associated with no preference and preference for a less intensive lifestyle treatment. Post-treatment follow-up of the trial results will determine if concordance between preference and treatment assignment influences outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Preventative Medicine, Rush University Medical Center, Chicago, IL, USA. katherine.iannuzzelli@gmail.com.
- Department of Preventative Medicine, Rush University Medical Center, Chicago, IL, USA.
Förderung
- William G. McGowan Charitable Fund
Zitieren
APA
Iannuzzelli, K., Suzuki, S., Karavolos, K., & Powell, L. H. (2025). Patient Preferences for Lifestyle Management in a Multi-site Randomized Lifestyle Trial for Remission of the Metabolic Syndrome. International Journal of Behavioral Medicine, 32(4), 486-494. https://doi.org/10.1007/s12529-024-10278-2
Vancouver
Iannuzzelli K, Suzuki S, Karavolos K, Powell LH. Patient Preferences for Lifestyle Management in a Multi-site Randomized Lifestyle Trial for Remission of the Metabolic Syndrome. International Journal of Behavioral Medicine. 2025;32(4):486-494. doi:10.1007/s12529-024-10278-2
BibTeX
@article{Iannuzzelli2025,
author = {Iannuzzelli, Katherine and Suzuki, Sumihiro and Karavolos, Kelly and Powell, Lynda H},
title = {Patient Preferences for Lifestyle Management in a Multi-site Randomized Lifestyle Trial for Remission of the Metabolic Syndrome},
journal = {International Journal of Behavioral Medicine},
year = {2025},
volume = {32},
number = {4},
pages = {486--494},
doi = {10.1007/s12529-024-10278-2}
}
EUVIMED